^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Endometrial Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Endometrial cancer: Systemic Therapy for Endometrial Carcinoma...Recurrent, Metastatic or High-risk Disease…Other recommended regimens…Carboplatin/paclitaxel/bevacizumab
    Secondary therapy:
    carboplatin + paclitaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the NCCN panel considers bevacizumab or temsirolimus as appropriate single-agent biologic therapy for patients who have progressed on previous cytotoxic chemotherapy.